IPA
IPA recorded revenue of $5.3 million, with two of its three sites delivering impressive double-digit growth rates year-over-year
IPA Saw Record Revenue of $24.5 Million FY 2024
BioStrand is driving revenue growth through its LENS ai platform, offering fee-for-service solutions while developing commercial products tailored to IPA's extensive client base of over 600 companies
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
READ THE INVESTOR PRESENTATION HERE
Hello Everyone,
I hope that you were watching our latest profile from last Thursday. It was sitting around 1.03 when we brought it to your attention.
It ran overnight and continues to make new highs daily as it just tapped 1.25. This translates to a massive 20%+ move overnight. When something noteworthy like that happens, we have to take a second to acknowledge it.
We are right back at you with another Nasdaq that is sitting under a buck and has never been profiled on our newsletter before.
Pull up IPA immediately.
No it's not a beer company, its actually a revenue generating Antibody / AI company that has been moving in the right direction.
IPA's proprietary technologies and products are positioned on the leading edge of antibody development, innovating their industry as a single source provider of the full complement of antibody discovery platforms.
They leverage multi-omics modelling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
IPA has expanded its technology suite to include over 80 in silico tools, potentially revolutionizing how new treatments are conceptualized and brought to market. The shift toward Al-driven methodologies by many of IPA's pharmaceutical partners underscores a broader industry trend towards more efficient, safer, and cost-effective drug development processes. The recent launch of a new interface for LENSai marks a significant milestone, facilitating its seamless integration by pharmaceutical companies, technology firms, and research hospitals.
Recently ranked by one of the pharmaceutical industry’s most trusted independent market research sources with the highest score for its antibody service portfolio, the company is comprised of a hybrid of disruptive technologies and leading-edge platforms for biotherapeutic drug discovery. IPA provides highly specialized, full-continuum therapeutic antibody discovery and development, with in silico machine intelligence designed to solve the unique challenges big data processing poses pharmaceutical companies.
By embedding The LENSai Integrated Intelligence Technology from BioStrand (a subsidiary of IPA) into every step of the IPA antibody discovery process, they set a new standard for potentially developing life-saving therapies faster, with more insight and more accuracy. The LENSai applications lend great cost and time efficiencies to their antibody discovery partners. Industry leading, robust contract research (CRO) laboratory capabilities, combined with the most advanced in silico technologies, mean acceleration and cost-savings in the race to the clinic.
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
September 16, 2024
Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENS ai
VICTORIA, British Columbia--(BUSINESS WIRE)-- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for the first quarter of its 2025 fiscal year (“FY25”), which ended July 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted.
"Our commitment to end-to-end in silico engineering of antibodies for challenging targets has delivered exceptional results. By harnessing our advanced computational capabilities, we've not only accelerated our R&D process, but also significantly reduced costs compared to traditional technologies,” stated Dr. Jennifer Bath, President and CEO. “Notably, two of our three wet lab locations reported impressive double-digit revenue growth this quarter, underscoring the effectiveness of our strategy. Our third site focused efforts on rebuilding its off-the-shelf inventory, a move designed to support future sales of higher-margin products. This balanced approach of driving immediate growth while strategically positioning for future profitability demonstrates our commitment to long-term value creation. Our innovative antibody development techniques, combined with astute operational decisions, reinforce our competitive edge in this dynamic market. We're confident that this multifaceted strategy will continue to drive sustainable growth and enhance shareholder value in the quarters to come.”
Business Highlights and Corporate Update
ImmunoPrecise continues to execute its growth strategy, focusing on scaling its AI-driven antibody drug discovery platforms, expanding its global client base, and optimizing operational efficiencies. The Company's comprehensive approach to antibody discovery and development is consistently yielding tangible outcomes. In the quarter ending July 31, 2024, ImmunoPrecise recorded revenue of $5.3 million, with two of its three sites delivering impressive double-digit growth rates year-over-year. While IPA's protein manufacturing site experienced a year-over-year decline this quarter, this was primarily due to an exceptionally strong performance in the previous year and rebuilding off-the-shelf inventory of higher-margin products. ImmunoPrecise's balanced approach of driving immediate growth while strategically positioning for the future underscores its commitment to long-term value creation and reinforces its competitive edge in the dynamic antibody market.
BioStrand is driving revenue growth through its LENS ai platform, offering fee-for-service solutions while developing commercial products tailored to IPA's extensive client base of over 600 companies. Recently, BioStrand achieved a significant breakthrough by developing and optimizing antibodies entirely through computer simulations, targeting a protein within the Tumor Microenvironment (TME). This achievement is particularly noteworthy given the TME's intricate nature and the lack of prior structural data on the target. Despite these formidable challenges, our team successfully navigated the complexities of end-to-end in silico antibody development in this demanding context. Building on this AI-driven success, BioStrand is now accelerating the rollout of advanced in silico antibody engineering solutions, positioning the company at the forefront of computational drug discovery and potentially opening new revenue streams in this high-growth market segment.
BioStrand is also making progress in developing applications for the AWS Marketplace. For context, the AWS Marketplace is a global platform that enables partners to leverage Amazon Web Services' technologies, programs, and expertise to build and deliver cutting-edge solutions. This marketplace provides BioStrand with enhanced visibility to a broader customer base, opening new opportunities for growth and collaboration while ensuring the delivery of high-quality, AI-driven SaaS solutions.
Talem Therapeutics and BioStrand have partnered to enhance Talem's lead therapeutic assets using BioStrand's LENS ai software suite, which includes over 80 in silico applications. This collaboration aims to increase the data quality and value of these assets. By leveraging LENS ai to refine existing lead candidates, the Company expects to improve their market readiness and commercial potential. The Company plans to soon release more details on these enhanced assets, demonstrating LENS ai 's utility in antibody engineering and its impact on asset value.
First Quarter FY25 Financial Results
- Revenue: Total revenue was $5.3 million, compared to revenue of $5.7 million in fiscal year 2024 (“FY24”) Q1. Project revenue generated $4.9 million, including projects using IPA’s proprietary B Cell Select® platform and IPA’s proprietary LENS ai platform, compared to $5.2 million in FY24 Q1. Product sales and cryostorage revenue were $0.4 million, compared to $0.5 million in FY24 Q1.
- Research & Development (R&D) Expenses: R&D expenses were $1.6 million, compared to $0.9 million in FY24 Q1, with the increase reflecting increased expenditures related to the build of the Company's LENS ai platform.
- Sales & Marketing (S&M) Expenses: S&M expenses were $0.7 million, compared to $1.1 million in FY24 Q1. The reduction in sales and marketing expenses reflect lower share-based expense and cost savings from our synergistic sales efforts across our comprehensive AI-enhanced antibody discovery and development services.
- General & Administrative (G&A) Expenses : G&A expenses were $4.2 million, compared to $4.0 million in FY24 Q1.
- Net Loss: Net loss of $4.0 million, or $(0.15) per share on a basic and diluted basis, compared to a net loss of $3.4 million or $(0.14) on a basic and diluted basis in FY24 Q1.
- Liquidity: Cash totaled $4.0 million as of July 31, 2024, compared to $6.8 million as of July 31, 2023.
ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology
August 19, 2024
Engineering antibodies in silico using LENS ai™ marks a significant milestone toward the complete de novo design of antibodies, aligning with IPA's vision to make groundbreaking and safer therapeutics instantly accessible and affordable.
Key takeaways:
- Highly Specific Binding of Novel Antibodies to a Tumor Microenvironment Protein of Previously Unknown Structure - Verified in Laboratory Setting.
- The Targeted Protein, Residing Within the Harsh Tumor Microenvironment, Represents a Key Challenge in Healthcare and the Treatment of Cancers
VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutics company, today announced a groundbreaking achievement: the ability to engineer antibodies entirely through computer simulations using LENS ai . This marks a significant milestone for the biotechnology industry. Additionally, the antibodies produced by IPA are highly specific to a challenging oncology target located within the Tumor Microenvironment (TME).
This achievement was made possible by the patented LENS ai technologies, which began from an exceptionally challenging starting point: the target protein had no previously known structural information. Despite this, the LENS ai platform was able to model the protein's structure and accurately engineer antibodies specifically tailored to bind to it. This is particularly significant because designing effective therapeutics without prior structural knowledge of the target is a major hurdle in drug discovery, often requiring extensive experimentation and resources. LENS ai 's ability to overcome this challenge entirely in silico highlights its advanced capabilities in computational biology and its potential to revolutionize the field of antibody engineering.
The potential therapies were engineered to bind exclusively to the oncology target under specific conditions. Importantly, it was demonstrated that these therapies do not bind to similar proteins known to be present on healthy cells and tissues, which is crucial because such binding typically leads to the negative side effects seen in chemotherapy. These findings highlight LENS ai 's ability to address one of the toughest challenges in optimizing antibodies for oncology.
“This marks a significant milestone for the biotechnology industry, demonstrating LENS ai 's ability to engineer highly specific and validated antibodies for the exceedingly difficult environment around tumors, and doing so entirely on a computer,” said Dr. Jennifer Bath, President and CEO of IPA. “This success, elevated by the fact that important details of the protein being targeted were unknown, represents a major feat in the application of LENS ai in generating targeted and specific therapies for the potential treatment of cancer. Moreover, our continuous advancements and integrations have significantly enhanced our ability to develop these therapies faster, more efficiently, and at a reduced cost compared to traditional methods.”
Historically, biologic drug discovery has been a risky, time-consuming, and expensive endeavor, with failure rates exceeding 90%. Recent data indicates that it now costs approximately $1.3 billion and takes an average of 10 to 15 years to bring a single new drug to market, with costs potentially rising even higher depending on the complexity of the drug and therapeutic area. The market has seen major successes like Humira, which has shown potential in the tumor microenvironment and has generated over $20 billion in annual sales. Similarly, Keytruda has demonstrated effectiveness in modulating the tumor microenvironment and has generated over $14 billion annually. However, the time, cost, and risk associated with developing such biologics have historically limited the number of these therapies that can be pursued, creating a bottleneck in the availability of life-saving treatments.
“The successful application of LENS ai , along with laboratory validation of these novel antibodies, underscores LENS ai ’s potential to accelerate the development of precision-targeted treatments, aimed at more effective cancer therapies with fewer side effects,” stated Dr. Dirk Van Hyfte, MD, PhD, Co-Founder and Head of Innovation at BioStrand, an IPA subsidiary. “What LENS ai has accomplished today is just one of the reasons we firmly believe in its ability to bring potentially life-changing biologics to patients with the power of our AI.”
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems. This recognition highlights BioStrand’s groundbreaking work in biotherapeutic research, which has made a significant impact and set a new standard for innovation in the industry.
The 2024 Impact Award acknowledges BioStrand’s innovative LENSai technology, selected from over 1,000 client projects for its remarkable contributions. The selection committee, chaired by Professor Roberto Zicari, identified BioStrand’s work based on three key criteria:
- Makes a significant difference: LENSai’s innovative approach has substantially advanced the field of biotherapeutics.
- Breaks new ground: The technology introduces novel methods and solutions, pushing the boundaries of current research and development.
- Sets an example: BioStrand’s achievements serve as a benchmark for other organizations, demonstrating excellence in innovation.
The award will be presented today at the InterSystems annual Global Summit, at the Gaylord National Resort and Convention Center in Maryland, USA. This premier event attracts industry leaders and top professionals from around the globe, including C-level executives, subject matter experts, visionary leaders, managers, directors, and developers. This year’s summit expects over 1,200 attendees from more than 28 countries.
The award celebration will take place today, from 10:30-11:00 AM ET, during a personalized award presentation session. The event offers an additional excellent opportunity for BioStrand and IPA to showcase their innovative contributions to a global audience.
“We are incredibly proud of BioStrand’s achievements and this recognition from InterSystems,” said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd. “The Impact Award underscores the significance of BioStrand’s pioneering work and reinforces our commitment to driving innovation in biotherapeutic research.”
For more information about the InterSystems Global Summit, the Impact Award, and to view Dr. Van Hyfte’s formal acceptance of the award please visit today’s Live Stream starting at 9am ET, at the InterSystems Global Summit 2024: https://lnkd.in/eYvZAhiH
About BioStrand BioStrand, a subsidiary of ImmunoPrecise Antibodies Ltd., specializes in innovative biotherapeutic research and development. BioStrand’s LENSai technology represents a groundbreaking approach in the field, driving significant advancements and setting new standards for innovation.
NEWS
September 26, 2024
September 16, 2024
September 9, 2024
August 26, 2024
August 23, 2024
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
August 19, 2024
July 29, 2024
July 23, 2024
July 16, 2024
July 15, 2024
June 27, 2024
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
June 25, 2024
June 12, 2024
June 10, 2024
June 4, 2024
March 28, 2024
March 20, 2024
March 14, 2024
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
March 7, 2024
March 4, 2024
MANAGEMENT TEAM
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
O22 HAS BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY A THIRD PARTY, MOMENTUM MEDIA, LLC FOR A ONE DAY IPA PROFILE.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.